Imagen de Portada

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Hepatology Research
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and Safety of Glecaprevir/Pibrentasvir in Children Aged 3–11 Years With Chronic Hepatitis C: A Real‐World, Prospective, Multicenter Study in Japan
por: Tatsuki Mizuochi, et al.
Publicado: (2025)

Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs
por: Takanori Suzuki, et al.
Publicado: (2024)

Population‐Based Molecular Surveillance of Hepatitis B Virus Genotypes in the Goto Islands, Japan: A Three Decade Study (1977–2008) of 916 Carriers
por: Ko Ko, et al.
Publicado: (2025)

Digital Polymerase Chain Reaction‐Based Fecal Streptococcus Quantification for Liver Fibrosis Assessment in Chronic Liver Disease
por: Nomura Nao, et al.
Publicado: (2025)

Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan
por: Hironori Ochi, et al.
Publicado: (2026)

Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy
por: Hayato Kawamura, et al.
Publicado: (2024)

A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan
por: Kinya Okada, et al.
Publicado: (2024)

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs
por: Kazuhiro Murai, et al.
Publicado: (2025)

Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021
por: Satoko Ohfuji, et al.
Publicado: (2024)

Comment on “Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan”
por: Haonan Jin
Publicado: (2026)

Letter to the Editor: “Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan”
por: Haigu Ke, et al.
Publicado: (2026)

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients
por: Nobuharu Tamaki, et al.
Publicado: (2026)

Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy
por: Takahiro Nakashima, et al.
Publicado: (2024)

Guidance for Liver Rehabilitation in Chronic Liver Disease
por: Shuji Terai, et al.
Publicado: (2026)

Serum alpha‐fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis
por: Hiroki Inada, et al.
Publicado: (2025)

The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging‐Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicenter Cohort Study in Japan
por: Takashi Nishimura, et al.
Publicado: (2026)

Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
por: Kazuya Kariyama, et al.
Publicado: (2025)

Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan
por: Tomomi Kogiso, et al.
Publicado: (2024)

Successful Retreatment of Glecaprevir‐Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy
por: Tatsuo Kanda, et al.
Publicado: (2025)

Post‐COVID‐19 Changes in Body Composition and Adiposity in Patients With Chronic Liver Disease: A Longitudinal Study From Japan
por: Akira Uchiyama, et al.
Publicado: (2025)

Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers
por: Sung Kwan Bae, et al.
Publicado: (2024)

Current Status and Challenges of Antithrombin Administrations in Cases of Portal Vein Thrombosis With Decreased Antithrombin Concentration in Japan
por: Hisashi Hidaka
Publicado: (2025)

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan
por: Kazumi Yamasaki, et al.
Publicado: (2026)

High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Emi Sometani, et al.
Publicado: (2024)

Lymphocyte‐to‐Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma
por: Satoshi Tanaka
Publicado: (2025)

Elevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease
por: Motoh Iwasa, et al.
Publicado: (2025)

Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”
por: Wei Huang, et al.
Publicado: (2024)

Autoimmune Hepatitis: Histopathological Diversity and Its Clinical Implications
por: Mina Komuta, et al.
Publicado: (2025)

Comparison of hepatitis B virus genotype B and C patients in Japan in terms of family history and maternal age at birth
por: Kosuke Sato, et al.
Publicado: (2025)

Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan
por: Yoshio Tokumoto, et al.
Publicado: (2025)

Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey
por: Yuki Kugiyama, et al.
Publicado: (2025)

Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”
por: Ritsuzo Kozuka, et al.
Publicado: (2024)

Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic Impact
por: Tomoko Tadokoro, et al.
Publicado: (2026)

Impact of PNPLA3 Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia
por: Takao Shirono, et al.
Publicado: (2025)

Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
por: Dong Wook Kim, et al.
Publicado: (2025)

Liver Transplantation in Japan: Registry by the Japanese Liver Transplantation Society
por: Koji Umeshita, et al.
Publicado: (2026)

Letter to ‘‘Circulating Myostatin Levels as a Prognostic Biomarker in Patients With Acute Liver Failure and Late‐Onset Hepatic Failure’’
por: Yanyan Zhang, et al.
Publicado: (2025)

Characteristic Hepatic Atrophy in Abemaciclib‐Induced Liver Injury: A Comparative Review of Three Cases
por: Yuwa Ando, et al.
Publicado: (2026)

Nationwide Engagement in an Interdisciplinary eLearning Program on Alcohol Dependence in Japan
por: Akihiko Shibamoto, et al.
Publicado: (2026)

Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis
por: Takao Miwa, et al.
Publicado: (2025)